The RTW Podcast cover art

The RTW Podcast

The RTW Podcast

By: RTW Investments LP
Listen for free

We’re witnessing a healthcare revolution, as medical and science innovations transform the lives of millions. Join as we speak to bright scientific minds, inspiring company founders and healthcare champions that are driving this exciting period of scientific discovery.

Subscribe to catch each episode as it goes live.

The content of this podcast does not constitute investment advice, an offer to provide investment advisory services, or an offer to sell or solicitation of an offer to buy an interest in any investment fund.

RTW Investments, LP 2023
Biological Sciences Economics Personal Finance Science
Episodes
  • ASCO: The Biggest Event in Oncology
    May 28 2026

    For decades, some cancers were a near-certain death sentence. Now, a new generation of cancer drugs—many coming from biotech, not big pharma—is changing that. RTW’s Chris Liu discusses ASCO 2026, and breakthroughs in pancreatic cancer, lung cancer, and other hard-to-treat tumors. What's driving the progress, why is it happening now, and what does it mean for the future of cancer care?

    PODCAST TEAM

    Producer & Director: Devon Leaver

    Editor: Dominique Guerra

    Production Coordinator: Ying Yu Lin

    Production Support: Annabelle Chan

    Production Assistant: Nicole M. Rosales

    Executive Editorial Advisor: Stephanie A. Sirota

    Research Consultant: Chris Liu

    Research Consultant: Julia Harper

    Research Consultant: Lauren Lee

    Theme Music: Yehezkel Raz

    Additional Music: APM Music

    Featuring by Chris Liu, Senior Research Analyst, moderated by Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments.

    FOLLOW US

    Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

    To make sure you never miss an episode, you can subscribe to the RTW podcast on YouTube, Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

    CHAPTERS

    00:00 - Introduction

    1:04 – The Evolution of Cancer Treatments

    3:19 - Unmet Needs in Oncology

    10:03 - Treating Pancreatic Cancer

    14:20 - The Importance of ASCO

    16:48 - The Rise of Chinese Biotech

    21:54 - Trends in Oncology

    23:42 - Outro

    DISCLAIMER

    This interview was given by Chris Liu, Senior Research Analyst, and moderated by Partner, and Chief Business Officer Stephanie Sirota, at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.

    Show More Show Less
    25 mins
  • Women's Health: An Investing Whitespace
    Apr 27 2026

    Menopause, perimenopause, and hormone replacement therapy (HRT) are reshaping the conversation around women’s health and longevity. OB/GYN Dr. Stephanie Lam explains the science, symptoms, and why women’s healthcare may represent a major investing whitespace.

    PODCAST TEAM

    Producer & Director: Devon Leaver

    Editor: Dominique Guerra

    Production Coordinator: Ying Yu Lin

    Production support: Annabelle Chan

    Executive Editorial Advisor: Stephanie Sirota

    Theme music: Yehezkel Raz

    Additional music: APM Music

    Featuring: Dr. Stephanie Lam, OB/GYN, Carnegie Women’s Health, moderated by Stephanie Sirota, Partner, Chief Business Officer, RTW Investments, LP.

    FOLLOW US

    Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

    To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

    CHAPTERS

    00:00 – Introduction

    00:55 - Dr. Lam’s Path to OB/GYN

    2:01 - Defining Menopause and Perimenopause

    5:05 - The Health Impact of HRT

    8:08 - A Holistic View of Women’s Health

    10:35 - GLPs and Women’s Healthcare

    14:25 - Investment Whitespaces in Women’s Health

    19:03 - Outro

    DISCLAIMER

    This interview was given by Dr. Stephanie Lam, OB/GYN at Carnegie Women’s Health in New York, and moderated by Stephanie Sirota, Partner, Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.

    Show More Show Less
    20 mins
  • Gene Editing: From CRISPR to Curative Medicine
    Mar 30 2026

    What if you could fix disease by rewriting DNA? From CRISPR to next-gen gene editing, Stephanie Sirota and Beam Therapeutics CEO John Evans break down base editing, prime editing, and the path to one-time cures.

    PODCAST TEAM

    Producer & Director: Devon Leaver

    Editor: Dominique Guerra

    Production Coordinator: Ying Yu Lin

    Production support: Annabelle Chan

    Executive Editorial Advisor: Stephanie Sirota

    Research Consultant: Piratip Pratumsuwan

    Theme music by: Yehezkel Raz

    Additional music: APM Music

    Featuring: John Evans, CEO and Board Member of Beam Therapeutics, moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments.

    FOLLOW US

    Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

    To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

    CHAPTERS

    00:00 – Introduction

    1:15 – Gene Editing, Gene Therapy, Base and Prime Editing

    4:18 – Challenges in Gene Editing

    6:09 – In Vivo and Ex Vivo

    9:33 – What is A1AT Deficiency?

    13:44 – Safety in Gene Editing

    15:52 – AI and Beam Therapeutics

    21:25 – John Evans’ Journey into Biotech

    23:06 – Outro

    DISCLAIMER

    This interview was given by John Evans, CEO and Board Member of Beam Therapeutics, and moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.

    Show More Show Less
    24 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet